Aktualności Neurologiczne,
Год журнала:
2023,
Номер
23(3), С. 111 - 117
Опубликована: Дек. 28, 2023
Multiple
sclerosis
is
a
heterogeneous
and
chronic
disease,
the
primary
goal
of
treatment
to
prevent
relapses
slow
progression
disability.
Ocrelizumab
generally
well-tolerated
disease-modifying
therapy
for
multiple
sclerosis,
with
high
efficacy
in
active
relapsing
forms,
valuable
method
delaying
disease
patients
progressive
form.
The
activity
defined
on
basis
clinical
course
or
radiological
findings
assessed
over
year.
occurrence
and/or
magnetic
resonance
imaging
taken
into
account.
In
line
recommendations
European
Committee
Treatment
Research
Sclerosis
Academy
Neurology,
as
well
accordance
guidelines
American
updated
2021,
depending
early
stage
choice
drug
should
be
motivated
by
higher
efficacy.
Recommendations
most
countries
Europe
around
world
are
based
above-mentioned
guidelines.
Poland,
modifying
were
developed
2023
experts
from
Neuroimmunology
Section
Polish
Neurological
Society.
B.29
programme
National
Health
Fund
Poland
allows,
1
July
2023,
addition
escalation,
using
induction
model
highly
effective
therapies
first-line
treatment.
Brain and Behavior,
Год журнала:
2024,
Номер
14(7)
Опубликована: Июль 1, 2024
Abstract
Introduction
Multiple
sclerosis
(MS)
is
a
debilitating
neurological
condition
affecting
nearly
one
million
people
across
the
United
States.
Among
most
prominent
symptoms
of
are
excessive
fatigue
and
daytime
sleepiness.
Numerous
clinical
trials
have
investigated
efficacy
modafinil
in
addressing
among
these
patients.
Objective
The
objective
present
study
to
assess
safety
for
treatment
MS.
Methodology
An
electronic
search
PUBMED,
ScienceDirect,
Cochrane
Central
was
conducted
articles
published
from
inception
December
2023
using
terms
such
as
“modafinil,”
“fatigue,”
“MS.”
Results
Seven
studies
were
included
our
analysis.
Modafinil
leads
meaningful
reduction
when
compared
with
placebo,
measured
by
Modified
Fatigue
Impact
Scale
[mean
difference
(MD)
=
−4.42
[−8.01,
−.84];
I
2
45%;
p
.02]
Epworth
Sleepiness
[MD
−.87
[−1.64,
−.10];
0%;
.03].
also
demonstrated
greater
risk
precipitating
adverse
events
(e.g.,
insomnia,
gastrointestinal
symptoms)
placebo
[RR
1.30
[1.03,
1.66];
In
quality‐of‐life
assessments,
associated
overall
improvement
well‐being
[standardized
mean
.18
[.01,
.35];
56%;
.04].
Conclusion
data
indicates
that
confers
therapeutic
benefit
treating
patients
MS
improves
quality
life;
however,
there
events.
Ultimately,
higher
evidence
may
be
required
better
inform
management.
Advances in Therapy,
Год журнала:
2024,
Номер
41(8), С. 3396 - 3406
Опубликована: Июнь 15, 2024
Diroximel
fumarate
(DRF)
and
dimethyl
(DMF)
are
orally
administered
disease-modifying
therapies
(DMTs)
for
multiple
sclerosis
(MS).
The
safety,
tolerability,
exploratory
efficacy
of
DRF
were
evaluated
in
the
phase
3
EVOLVE-MS-1
study.
No
Evidence
Disease
Activity
(NEDA-3)
is
a
composite
endpoint
used
clinical
trials
MS
defined
as
no
relapse,
24-week
confirmed
disability
progression
(CDP),
new/newly
enlarging
T2
lesions,
new
gadolinium-enhancing
lesions.
As
NEDA
outcomes
studies
may
be
confounded
by
initial
disease
activity,
objective
this
analysis
was
to
evaluate
NEDA-3
newly
enrolled
patients
who
re-baselined
after
approximately
7
weeks.
Patients
entered
either
or
having
completed
5-week
EVOLVE-MS-2
study
DMF.
Magnetic
Resonance
Imaging
(MRI)
performed
at
baseline
before
each
(approx.
weeks
apart)
48
96
EVOLVE-MS-1.
Therefore,
entering
from
on
reported
prior
DRF,
DMF,
de
novo
patient
groups.
Of
1057
EVOLVE-MS-1,
239
(22.6%)
had
rolled
over
receiving
("prior
DRF"),
225
(21.3%)
DMF
DMF"),
593
(56.1%)
("de
novo").
At
week
48,
Kaplan-Meier
estimates
72.3%
(prior
DRF),
72.1%
DMF),
62.1%
(de
novo);
96,
50.2%
48.2%
36.5%
novo).
In
re-baselining
weeks,
half
DRF-treated
achieved
compared
with
not
re-baselined.
Re-baselining
useful
assessing
DMTs
mitigating
influence
activity
onset
efficacy.
NCT03093324
(EVOLVE-MS-2);
NCT02634307
(EVOLVE-MS-1).
Diseases,
Год журнала:
2024,
Номер
12(6), С. 127 - 127
Опубликована: Июнь 16, 2024
Multiple
sclerosis
(MS)
is
a
chronic,
progressive
neurological
disorder
that
significantly
impacts
quality
of
life
and
functionality.
Ocrelizumab,
monoclonal
antibody
targeting
CD20-positive
B
cells,
has
emerged
as
treatment
for
relapsing-remitting
MS
(RRMS).
This
study
aimed
to
assess
the
impact
ocrelizumab
on
disease
progression
over
longitudinal
course,
utilizing
clinical
criteria
magnetic
resonance
imaging
(MRI)
analyses.
Conducted
at
Neurology
Department
Pius
Brinzeu
Clinical
Emergency
Hospital
in
Western
Romania
from
2020
2023,
this
observational
enrolled
93
patients
with
RRMS
who
commenced
therapy.
The
employed
Expanded
Disability
Status
Scale
(EDSS)
MRI
evaluate
progression,
while
was
assessed
using
World
Health
Organisation
Quality
Life
(WHOQOL)
questionnaire,
Beck
Depression
Index
(BDI),
MOCA
scales.
Significant
improvements
were
observed
post-treatment.
EDSS
scores
decreased
4.61
4.08
(p
=
0.038),
indicating
reduced
disability.
analyses
showed
substantial
decrease
expansive
lesions
(from
67.74%
26.88%,
p
<
0.001)
an
increase
stationary
32.26%
73.12%,
0.001).
notable
physical
58.42
64.84,
0.005)
environmental
domains
63.21
68.44,
0.033).
Cognitive
functions,
via
Montreal
Assessment
(MOCA),
significant
total
score
20.38
22.30
Subgroup
analysis
revealed
more
pronounced
effects
females
younger
patients,
reduction
depressive
symptoms
measured
by
BDI
14.35
11.62,
0.003).
Ocrelizumab
activity
disability
demonstrated
findings.
cognitive
functions
also
considerable
enhancements.
These
findings
support
ocrelizumab’s
efficacy
not
only
managing
but
improving
overall
patient
well-being.
Frontiers in Neurology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 24, 2024
Ublituximab
is
a
novel
anti-CD20
monoclonal
antibody
glycoengineered
for
enhanced
antibody-dependent
cellular
cytotoxicity.
The
phase
3
ULTIMATE
I
and
II
studies
showed
significant
improvements
in
annualized
relapse
rate,
total
number
of
gadolinium-enhancing
(Gd+)
T1
lesions,
new
or
enlarging
T2
at
Week
96,
as
well
improvement
the
proportion
participants
with
no
evidence
disease
activity
(NEDA)
from
Weeks
24-96
ublituximab
vs.
teriflunomide.
Practical Neurology,
Год журнала:
2024,
Номер
25(1), С. 18 - 24
Опубликована: Ноя. 11, 2024
The
Association
of
British
Neurologists
last
published
guidelines
on
disease-modifying
treatment
(DMT)
in
multiple
sclerosis
(MS)
2015.
Since
then,
additional
DMTs
have
been
licensed
and
approved
for
prescribing
within
the
National
Health
Service
relapsing-remitting
MS,
early
primary
progressive
MS
active
secondary
MS.
This
updated
guidance
provides
a
consensus-based
approach
to
using
DMTs.
We
provide
recommendations
eligibility,
starting,
monitoring,
switching
stopping
DMTs;
pregnancy;
equitable
access
DMT;
autologous
haemopoietic
stem-cell
transplantation;
use
generics.
highlight
best
practice
where
it
exists
discuss
future
priorities.
Consilium Medicum,
Год журнала:
2024,
Номер
26(11), С. 752 - 758
Опубликована: Дек. 16, 2024
Current
approaches
to
treating
multiple
sclerosis
aim
at
controlling
disease
activity.
Despite
the
variety
of
agents
that
have
proven
their
effectiveness
and
were
introduced
in
practice
last
decade,
use
interferon
β
group
remains
relevant.
The
article
presents
clinical
cases
long-term
interferons
sclerosis.
Aktualności Neurologiczne,
Год журнала:
2023,
Номер
23(3), С. 111 - 117
Опубликована: Дек. 28, 2023
Multiple
sclerosis
is
a
heterogeneous
and
chronic
disease,
the
primary
goal
of
treatment
to
prevent
relapses
slow
progression
disability.
Ocrelizumab
generally
well-tolerated
disease-modifying
therapy
for
multiple
sclerosis,
with
high
efficacy
in
active
relapsing
forms,
valuable
method
delaying
disease
patients
progressive
form.
The
activity
defined
on
basis
clinical
course
or
radiological
findings
assessed
over
year.
occurrence
and/or
magnetic
resonance
imaging
taken
into
account.
In
line
recommendations
European
Committee
Treatment
Research
Sclerosis
Academy
Neurology,
as
well
accordance
guidelines
American
updated
2021,
depending
early
stage
choice
drug
should
be
motivated
by
higher
efficacy.
Recommendations
most
countries
Europe
around
world
are
based
above-mentioned
guidelines.
Poland,
modifying
were
developed
2023
experts
from
Neuroimmunology
Section
Polish
Neurological
Society.
B.29
programme
National
Health
Fund
Poland
allows,
1
July
2023,
addition
escalation,
using
induction
model
highly
effective
therapies
first-line
treatment.
